COSCIENS Abandons Pharma, Bets Future on Skincare Ingredients

By Michelle Bell

TORONTO, ONTARIO – March 05, 2026 – COSCIENS Biopharma Inc. today announced a dramatic strategic pivot, ceasing all funding for its German biopharmaceutical subsidiaries and effectively ending its ambitions in the drug development sector. The move, which will lead to the insolvency of Aeterna Zentaris GmbH and Zentaris IVF GmbH, involves surrendering all rights to its main pharmaceutical asset, Macrilen®, a drug once seen as a cornerstone of the company's future.

In a decisive break from its past, the Toronto-based life science company is shedding its historically loss-making pharma arm to concentrate entirely on its profitable business: developing plant-based active ingredients for the global skincare industry. The decision marks the culmination of a strategic review prompted by a critical clinical trial failure that shattered hopes for Macrilen's market expansion.

"The Board did not make this decision lightly, but we firmly believe it marks a significant and positive step towards the Company’s goal of achieving profitability," stated Peter Puccetti, Interim CEO and Chairman of the Board, in a press release. The company will now focus on maximizing its active ingredients business and evaluating new opportunities in that space.

The End of the Macrilen Era

The story of Macrilen (macimorelin) is a cautionary tale of the immense challenges in pharmaceutical commercialization. The drug, an oral test for diagnosing adult growth hormone deficiency (AGHD), had achieved the significant milestone of securing approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Marketed as Macrilen® in the U.S. and Ghryvelin® in Europe, it represented a major scientific and regulatory success.

However, commercial success remained elusive. The company's biopharmaceutical division consistently operated at a loss, its long-term viability pinned on the hope of expanding Macrilen’s use into the pediatric market. This hope was decisively crushed by the disappointing results of its Phase 3 DETECT trial, which evaluated the drug for diagnosing Childhood Onset Growth Hormone Deficiency.

The trial failed to meet its primary efficacy endpoint. A subsequent Type C meeting with the FDA to discuss the data proved to be a "significant setback," effectively closing the door on a straightforward path to pediatric approval in the U.S. and gutting the financial case for the drug's future.

While quarterly reports showed modest revenue increases for Macrilen—growing by $1.1 million over the course of 2024—these gains were insufficient to offset the high costs of pharmaceutical research, development, and marketing. Even a newly signed distribution agreement in late 2025 for parts of Asia, which included a minimum initial order of approximately €800,000, was not enough to alter the grim financial calculus. The company determined that continuing to fund the biopharmaceutical business was no longer a viable path for its shareholders.

A Strategic Shift to Skincare

With the door closing on pharma, COSCIENS is turning its full attention to a seemingly more stable and profitable venture: its active ingredients business. The company leverages proprietary extraction technology to produce Avenanthramides and Beta Glucan from oats. These ingredients are not speculative future products; they are already key components in skincare formulations from global giants like Aveeno, Dove, and Neutrogena.

Avenanthramides are prized for their anti-inflammatory and antioxidant properties, while Oat Beta Glucan is valued for its ability to replenish the skin's moisture barrier and promote healing. The pivot allows COSCIENS to capitalize on a powerful and growing consumer trend. The global market for natural and plant-based cosmetic ingredients is booming, projected to grow at a compound annual growth rate of over 7% to reach nearly $1.5 billion by 2033.

This growth is fueled by a seismic shift in consumer behavior toward "clean beauty," sustainability, and a deep-seated preference for chemical-free products. With over 40% of shoppers actively seeking natural alternatives, COSCIENS is positioning itself to be a key supplier in a high-demand market. While the company's own financial reports have shown some recent quarterly revenue decreases in this segment, the strategic bet is that the underlying market tailwinds provide a more reliable path to growth than the volatile, high-stakes world of drug development.

A Painful Path to Profitability

Today's announcement is the most dramatic step in a series of aggressive restructuring measures undertaken by COSCIENS over the past year to stabilize its finances. The company has been on a relentless drive to cut costs and streamline its operations.

In 2025, COSCIENS voluntarily delisted its stock from the Nasdaq exchange to reduce regulatory costs, implemented a company-wide Zero-Based Budgeting system to scrutinize every expense, and reduced its total workforce by 27%. These efforts had already begun to bear fruit, with operating expenses in the third quarter of 2025 dropping a staggering 59% compared to the previous year.

Shedding the German subsidiaries and the entire Macrilen infrastructure is expected to result in a further "significant reduction" in ongoing operating expenses, accelerating the company's journey toward its stated goal of profitability. The move will, however, have a considerable human cost. The expected insolvency of Aeterna Zentaris GmbH and Zentaris IVF GmbH will directly impact the employees at those German facilities, who now face an uncertain future.

The market's initial reaction has been cautious, reflecting the severity of the decision. For the biopharmaceutical industry, the arc of Macrilen serves as a stark reminder that regulatory approval is not a guaranteed ticket to commercial success. It highlights the brutal economic realities that can force a company to abandon years of scientific investment in favor of a more pragmatic, if less glamorous, path to survival.